Biomerica (BMRA) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomerica (BMRA) has outperformed Intellia Therapeutics (NTLA) over the past year, losing 34.4% versus a loss of 48.5%. Over five years, NTLA leads with a -90.3% price change compared with -95.7% for BMRA. Intellia Therapeutics is the larger company by market cap ($1.83 billion vs $8.4 million), about 217.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | NTLA |
|---|---|---|
| Share price | $1.84 | $13.07 |
| Market cap | $8.44M | $1.83B |
| 1-day change | -1.86% | +3.73% |
| YTD return | -25.00% | +40.16% |
| 1-year return | -34.38% | -48.51% |
| 5-year return | -95.74% | -90.34% |
| Forward P/E | 4.71 | — |
| EPS (TTM) | $-1.30 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.67M |
| Revenue growth (YoY) | — | +16.92% |
| Net income (latest FY) | — | $-412.69M |
| Operating margin | — | -651.67% |
| Net margin | — | -609.85% |
| 52-week high | $3.21 | $28.25 |
| 52-week low | $1.45 | $7.95 |
| Distance from 52-week high | -42.83% | -53.73% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +76.82% |
| Average volume | 70.88K | 4.26M |
| Shares outstanding | 4.60M | 140.13M |
| Employees | 50 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 217.0 times larger than Biomerica by market value ($1.83B vs $8.44M).
- BMRA has outperformed NTLA by 14.1 percentage points over the past year.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 50 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
BMRA vs NTLA FAQ
Which is bigger, Biomerica or Intellia Therapeutics?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.83B compared with $8.44M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or NTLA?
BMRA returned -34.38% over the past 12 months, compared with -48.51% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.